Publications by authors named "Jasminka Dragovic"

Claim this Profile
I
Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor.
James M Apgar, Robert R Wilkening, Dann L Parker, Dongfang Meng, Kenneth J Wildonger, Jasminka Dragovic

Bioorg Med Chem Lett· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-5204: An orally active β-1,3-glucan synthesis inhibitor.
James M Apgar, Robert R Wilkening, Dann L Parker, Dongfang Meng, Kenneth J Wildonger, Jasminka Dragovic

Bioorg Med Chem Lett· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin.
James M Apgar, Robert R Wilkening, Mark L Greenlee, James M Balkovec, Amy M Flattery, Jasminka Dragovic

Bioorg Med Chem Lett· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.
Harry R Chobanian, Yan Guo, Ping Liu, Thomas J Lanza, Marc Chioda, Jasminka Dragovic

Bioorg Med Chem· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.
Harry R Chobanian, Yan Guo, Ping Liu, Marc Chioda, Thomas J Lanza, Jasminka Dragovic

ACS Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases.
Xiaoyan Chu, Zuo Zhang, Jocelyn Yabut, Sarah Horwitz, John Levorse, Jasminka Dragovic

Mol Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.
Ping Liu, Thomas J Lanza, Marc Chioda, Carrie Jones, Harry R Chobanian, Jasminka Dragovic

ACS Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridinesulfonylureas and pyridinesulfonamides as selective bombesin receptor subtype-3 (BRS-3) agonists.
Michael M-C Lo, Harry R Chobanian, Oksana Palyha, Yanqing Kan, Theresa M Kelly, Jasminka Dragovic

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.
Milana Maletic, Aaron Leeman, Michael Szymonifka, Steven S Mundt, Hratch J Zokian, Jasminka Dragovic

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.
Xiao-Ming Guan, Joseph M Metzger, Liming Yang, Kate A Raustad, Sheng-Ping Wang, Jasminka Dragovic

J Pharmacol Exp Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.
Iyassu K Sebhat, Christopher Franklin, Michael M-C Lo, David Chen, James P Jewell, Jasminka Dragovic

ACS Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
Cheng Guo, Peter R Guzzo, Mark Hadden, Bruce J Sargent, Larry Yet, Jasminka Dragovic

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, orally active benzimidazole glucagon receptor antagonists.
Ronald M Kim, Jiang Chang, Ashley R Lins, Ed Brady, Mari R Candelore, Jasminka Dragovic

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenylcyclobutyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
Yuping Zhu, Steven H Olson, Donald Graham, Gool Patel, Anne Hermanowski-Vosatka, Jasminka Dragovic

Bioorg Med Chem Lett· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Xin Gu, Jasminka Dragovic, Gloria C Koo, Sam L Koprak, Cheryl LeGrand

Bioorg Med Chem Lett· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
Dong-Ming Shen, Fengqi Zhang, Edward J Brady, Mari Rios Candelore, Qing Dallas-Yang, Jasminka Dragovic

Bioorg Med Chem Lett· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).
Lan Zhu, Constantin Tamvakopoulos, Dan Xie, Jasminka Dragovic, Xiaolan Shen

J Biol Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis